The strong cash runway reduces near-term dilution risk, supporting execution through key 2026–2027 clinical catalysts. Traders should monitor JADE101 interim data in Q2 2026 as the next major value inflection point, though continued losses will pressure sentiment absent positive trial outcomes.
Price Chart
Executive Summary
Jade Biosciences reported its full-year 2025 financial results, highlighting a strong cash position of $336.2 million following $180 million in private placements, enabling a runway into mid-2028. The company advanced its pipeline with JADE101 in Phase 1 trials and provided timelines for upcoming clinical milestones across JADE101, JADE201, and JADE301. However, net loss widened to $127.4 million amid rising R&D and G&A expenses.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments totaled $336.2 million as of December 31, 2025, up from $69.4 million at the end of 2024.
- Company raised $180 million via two private placements in Q4 2025.
- R&D expenses increased to $93.1 million in 2025 from $31.2 million in the 2024 inception period.
- Net loss for 2025 was $127.4 million, up from $47.0 million in 2024.
- Phase 1 interim data for JADE101 expected in Q2 2026; Phase 2 trial in IgA nephropathy to start mid-2026.
- JADE201 first-in-human trial expected in Q2 2026; JADE301 trial to begin in first half of 2027.
Financial Impact
Cash position increased by $266.8 million YoY to $336.2 million, but net loss more than doubled to $127.4 million. R&D spend increased 198% YoY.
Risk Factors
- High cash burn: $127.4M net loss in 2025 raises sustainability concerns beyond 2028 if no additional funding or revenue is secured.
- Clinical-stage risk: All programs are pre-revenue; failure in upcoming trials could significantly impact valuation.
- Dilution risk: Private placements likely diluted existing shareholders, though exact terms are not disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250954 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers